Allarity Therapeutics, Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Allarity Therapeutics is in Stage 4, the downtrend phase, now in week 2 (since Oct 12, 2026). It closed at $0.85, 52.1% below its 52-week high and below its 200-day average, which is falling.

$0.85

-5.09% today

$13.5M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ALLR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 90w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 90w → S1 4w → S4 3w → S1 4w → S4 3w → S1 2w → S2 12w → S3 7w → S4 10w → S1 4w → S4 1w → S1 3w → S2 9w → S3 12w → S4 2w current

Total tracked: 165 weeks across 15 stage runs.

ALLR among Biotechnology330th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…330	ALLRAllarity Therapeutics, Inc.	Stage 4 · wk 2	27	−18.6%

vs 52W High

-52.1%

$0.81 lo$1.77 hi

52.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-30.9%

200 DMA: $1.23 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.80x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-18.6%

-28.8%

-39.5%

YTD

-25.7%

-42.8%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.80x

2026-10-21S4

Wk 2 · Vol 0.78x

2026-10-20S4

Wk 2 · Vol 0.96x

2026-10-19S4

Wk 2 · Vol 0.77x

2026-10-16S4

Wk 1 · Vol 2.12x

2026-10-15S4

Wk 1 · Vol 3.07x

2026-10-14S4

Wk 1 · Vol 0.60x

2026-10-13S4

Wk 1 · Vol 1.06x

2026-10-12S43→4

Wk 1 · Vol 4.25x

2026-10-09S3

Wk 13 · Vol 1.00x

2026-10-08S3

Wk 12 · Vol 0.66x

2026-10-07S3

Wk 12 · Vol 0.84x

Moving averages & range

50 DMA

$1.15

200 DMA

$1.23

52W High

$1.77

52W Low

$0.81

5D Low

$0.85

Resistance levels (recent highs)

20d High

$1.05

60d High

$1.43

120d High

$1.77

250d High

$1.77

Next resistance

+24.0%

to 20d High

ROE

-157.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.8

Allarity Therapeutics: quick answers

What stage is Allarity Therapeutics in?

As of Oct 22, 2026, Allarity Therapeutics (ALLR) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 12, 2026 and is in week 2. What the four stages mean

Is Allarity Therapeutics in an uptrend?

No. Allarity Therapeutics is in a Stage 4 downtrend. It trades 30.9% below its 200-day average, which is falling.

How far is Allarity Therapeutics from its 52-week high?

Allarity Therapeutics closed at $0.85 on Oct 22, 2026, 52.1% below its 52-week high of $1.77. Its 52-week low is $0.81.

How has Allarity Therapeutics performed over the past year?

As of Oct 22, 2026, Allarity Therapeutics is down 42.8% over the past year and down 25.7% so far in 2026.

Which sector and industry is Allarity Therapeutics in?

Allarity Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.